H.C. Wainwright Starts Lexicon Pharmaceuticals (LXRX) at Buy

October 7, 2016 7:18 AM EDT
Get Alerts LXRX Hot Sheet
Price: $14.23 -3.53%

Rating Summary:
    5 Buy, 3 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 11
Trade LXRX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

H.C. Wainwright initiated coverage on Lexicon Pharmaceuticals (NASDAQ: LXRX) with a Buy rating and a price target of $26.

Analyst Shaunak Deepak said, "Strong partnerships, positive pivotal data, and over $400M in cash at 2Q, put Lexicon in an enviable position going into 2017, in our opinion. We would be buyers of LXRX going into the December readout of the second inTandem2 pivotal trial for sotagliflozin in type 1 diabetes and the February FDA approval decision for telotristatethyl for carcinoid syndrome."

For an analyst ratings summary and ratings history on Lexicon Pharmaceuticals click here. For more ratings news on Lexicon Pharmaceuticals click here.

Shares of Lexicon Pharmaceuticals closed at $18.50 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

H.C. Wainwright

Add Your Comment